Hydrocortamate

Summary

Hydrocortamate (CHEMBL1201263) is an approved small-molecule anti-inflammatory drug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 475.6 Da · C27H41NO6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201263
Name	Hydrocortamate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	84088
ChEBI	CHEBI:50851
Molecular formula	C27H41NO6
Molecular weight	475.6
InChIKey	FWFVLWGEFDIZMJ-FOMYWIRZSA-N

SMILES: CCN(CC)CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)O

IUPAC name: [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate

Pharmacological roles (ChEBI): anti-inflammatory drug, immunosuppressive agent.

Also known as: Hidrocortamato, Hydrocortamate, SID170465314, HYDROCORTAMATE

Parent form; salt/anhydrous children: CHEMBL1200635

Patent coverage: 1,401 distinct patent families (5,488 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).